Loading company…
Riskpilot
← Back to search
Sign in
Get full access
SØRREISA APOTEK AS
AS
Active
Org 929588622
Storveien 9, 9310 Sørreisa
Retail sale of pharmaceutical products · NACE 4773
Est. 2022
11 employees
Watchlist
Share
Overview
Financials
People & ownership
Related companies
Revenue 2024
NOK 20,8M
+20% vs 2023
EBITDA margin
7.6%
+57% vs 2023
Equity ratio
38.2%
Financial strength
Net profit 2024
NOK 997K
+74% vs 2023
EBITDA — year on year
NOK millions
3M
2M
1M
1M
0M
0M
2022
1M
+100%
2023
2M
+100%
2024
Key figures
Annual report 2024
Revenue
NOK 20,8M
+20%
EBITDA
NOK 1,6M
+57%
Net profit
NOK 997K
+74%
Total assets
NOK 5,2M
+28%
Equity
NOK 2M
+101%
Employees
11
—
Company information
Legal name
SØRREISA APOTEK AS
Org number
929588622
Legal form
Aksjeselskap
NACE code
4773 · Retail sale of pharmaceutical products
Founded
2. august 2022
Share capital
NOK 600 000
Employees
11 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Daglig leder eller styrets leder alene.
Company purpose
Salg av apotekvarer og andre farmasøytiske tjenester.
Contact
Address
Storveien 9, 9310 Sørreisa
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Retail sale of pharmaceutical products
Companies in Sørreisa
All Norway companies
Revenue
NOK millions
0M
6M
12M
18M
24M
2M
2022
17M
2023
21M
2024
EBITDA
NOK millions
0M
1M
1M
2M
2M
0M
2022
1M
2023
2M
2024
Income statement
NOK thousands
Item
2022
2023
2024
Revenue
1 680
17 328
20 755
Staff expenses
−354
−2 506
−2 499
EBITDA
−199
1 007
1 581
Depreciation & amort.
−35
−215
−218
EBIT
−233
793
1 363
Net financials
−7
−56
−63
Profit before tax
−240
737
1 299
Tax
−53
163
302
Net profit
−187
574
997
Balance sheet
NOK thousands
Item
2022
2023
2024
Total assets
4 549
4 054
5 192
Equity
413
986
1 983
Long-term debt
1 100
941
697
Short-term debt
3 036
2 126
2 512
Total debt
4 136
3 067
3 209
Financial ratios
5-year trend
EBITDA margin
7.6%
This company
15.8%
Market median
-52% vs market
2022
2024
Equity ratio
38.2%
This company
38.2%
Market median
+0% vs market
2022
2024
Return on equity
50.3%
This company
18.4%
Market median
+173% vs market
2022
2024
Net profit margin
4.8%
This company
8.1%
Market median
-41% vs market
2022
2024
Asset turnover
4.00×
This company
1.12×
Market median
+257% vs market
2022
2024
Debt / equity
1.62×
This company
0.62×
Market median
-161% vs market
2022
2024
Annual reports & filings
Annual report 2024
Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Brønnøysundsregistrene · Period 2022-06-30 – 2022-12-31
View
PDF
Management
Actively employed in the business
Name
Role
Member since
Current (1)
ZA
Zain-Ul Abideen
Chief Executive Officer
Chief Executive Officer
2022
Board of directors
Non-executive oversight
No data on file.
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
Zasha Invest As
Company
100%
100%
2024
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
Zasha Invest As
SØRREISA APOTEK AS
(this company)
Board network connections
Board members of SØRREISA APOTEK AS also hold positions in
0
other companies.
Person
Role here
Other companies
Zain-Ul Abideen
Chief Executive Officer
0 companies